These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16565234)

  • 1. Metabolic syndrome and cardiovascular risk in primary hypertension.
    Ratto E; Leoncini G; Viazzi F; Vaccaro V; Parodi A; Falqui V; Conti N; Tomolillo C; Deferrari G; Pontremoli R
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S120-2. PubMed ID: 16565234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic syndrome in hypertension: European society of hypertension position statement.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
    J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):359-67. PubMed ID: 15025845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome.
    Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
    Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive therapy in patients with metabolic syndrome.
    Segura J; Ruilope LM
    Curr Opin Nephrol Hypertens; 2006 Sep; 15(5):493-7. PubMed ID: 16914961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
    Ruilope L; Kjeldsen SE; de la Sierra A; Mancia G; Ruggenenti P; Stergiou GS; Bakris GL; Giles TD
    Blood Press; 2007; 16(2):72-9. PubMed ID: 17612904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.
    Deedwania PC; Schmieder R
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S12-8. PubMed ID: 16986230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
    Zarich SW
    Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the renin-angiotensin system in the pathophysiology, prevention, and treatment of renal impairment in patients with the cardiometabolic syndrome or its components.
    Alpert MA; Govindarajan G; Del Rosario ML; Reisin E
    J Cardiometab Syndr; 2009; 4(1):57-62. PubMed ID: 19245518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
    Hilgers KF; Mann JF
    Nephrol Dial Transplant; 2008 Nov; 23(11):3389-91. PubMed ID: 18687734
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic syndrome in subjects with essential hypertension: relationships with subclinical cardiovascular and renal damage.
    Mulé G; Cottone S; Nardi E; Andronico G; Cerasola G
    Minerva Cardioangiol; 2006 Apr; 54(2):173-94. PubMed ID: 16778751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hypertension and other cardiovascular risk factors in patients with metabolic syndrome.
    Suzuki T; Homma S
    Med Clin North Am; 2007 Nov; 91(6):1211-23, x. PubMed ID: 17964917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolic syndrome and its cardiovascular manifestations.
    Sánchez-Torres RJ; Delgado-Osorio H
    Bol Asoc Med P R; 2005; 97(4):271-80. PubMed ID: 16599068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of hypertension in the cardiometabolic syndrome.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G
    J Hypertens; 2009 Mar; 27(3):441-51. PubMed ID: 19262221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs.
    Staessen JA; Thijs L; Li Y; Kuznetsova T; Richart T; Wang J; Birkenhäger WH
    Curr Opin Cardiol; 2007 Jul; 22(4):335-43. PubMed ID: 17556887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome: at the crossroads of cardiorenal risk.
    Natali A; Pucci G; Boldrini B; Schillaci G
    J Nephrol; 2009; 22(1):29-38. PubMed ID: 19229816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control.
    Sarafidis PA; Bakris GL
    QJM; 2006 Jul; 99(7):431-6. PubMed ID: 16766516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glomerular filtration rate and cardiovascular risk: prognostic and therapeutic implications].
    Ratto E; Leoncini G; Viazzi F; Pontremoli R
    G Ital Nefrol; 2008; 25(1):21-31. PubMed ID: 18264915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.